IPHA - Innate Pharma S.A.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.57
+0.29 (+3.91%)
At close: 3:30PM EST
Stock chart is not supported by your current browser
Previous Close7.28
Open7.62
Bid7.00 x 1300
Ask7.85 x 1200
Day's Range7.43 - 7.68
52 Week Range5.61 - 8.24
Volume15,658
Avg. Volume65,742
Market Cap605.542M
Beta (5Y Monthly)0.26
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.00
  • Should You Be Excited About Innate Pharma S.A.'s (EPA:IPH) 17% Return On Equity?
    Simply Wall St.

    Should You Be Excited About Innate Pharma S.A.'s (EPA:IPH) 17% Return On Equity?

    While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

  • ACCESSWIRE

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Innate Pharma S.A. - IPHA

    NEW YORK, NY / ACCESSWIRE / January 14, 2020 / Pomerantz LLP is investigating claims on behalf of investors of Innate Pharma S.A. ("Innate" or the "Company") (NASDAQ:IPHA). Such investors ...

  • GlobeNewswire

    French Regulatory Agency Agrees lacutamab TELLOMAK Trial Can Resume Recruitment in Sezary Syndrome and mycosis fungoides

    Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the French National Agency for Medicines and Health Product Safety (ANSM) has agreed that the lacutamab (IPH4102) TELLOMAK Phase II trial can resume recruitment of new patients with relapsed/refractory Sézary syndrome and mycosis fungoides (MF) who have received at least two lines of prior systemic therapy. Following discussions with the Company, the ANSM decision to allow new patient recruitment to resume in Sézary syndrome and MF in France is based on an assessment of the unmet medical need and the lack of currently available standard of care options.

  • GlobeNewswire

    French regulatory agency agrees lacutamab TELLOMAK trial can resume recruitment in Sézary syndrome and mycosis fungoides

    Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the French National Agency for Medicines and Health Product Safety (ANSM) has agreed that the lacutamab (IPH4102) TELLOMAK Phase II trial can resume recruitment of new patients with relapsed/refractory Sézary syndrome and mycosis fungoides (MF) who have received at least two lines of prior systemic therapy. Following discussions with the Company, the ANSM decision to allow new patient recruitment to resume in Sézary syndrome and MF in France is based on an assessment of the unmet medical need and the lack of currently available standard of care options.

  • ACCESSWIRE

    Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Innate Pharma S.A. (IPHA)

    NEW YORK, NY / ACCESSWIRE / January 10, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers Innate Pharma S.A. ("Innate" or the Company") ...

  • GlobeNewswire

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Innate Pharma S.A.  - IPHA

    Pomerantz LLP is investigating claims on behalf of investors of Innate Pharma S.A. (“Innate” or the “Company”) (NASDAQ: IPHA). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Innate and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

  • GlobeNewswire

    INNATE PHARMA PROVIDES UPDATE FROM REGULATORY AGENCIES ON LACUTAMAB TELLOMAK TRIAL

    Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced a regulatory update regarding its TELLOMAK Phase II trial, evaluating the efficacy and safety of lacutamab (IPH4102) in patients with advanced T-cell lymphomas. The Company has been in ongoing discussions with regulatory authorities regarding Good Manufacturing Practice (GMP) deficiencies at the Company’s manufacturing subcontractor site that manages the fill and finish operations of the lacutamab clinical vials. Based on these discussions, on December 13, 2019, the Company decided to suspend enrollment of new patients in the TELLOMAK trial, except in Italy where the clinical trial has been suspended.

  • Benzinga

    The Daily Biotech Pulse: Canadian Approval For Amarin's Vascepa, Innate Pharma's Blood Cancer Drug Accepted For Review In Europe

    The following is a roundup of top developments in the biotech space over the last 24 hours.  Scaling The Peaks (Biotech stocks that hit 52-week highs on Dec. 31.) Aptose Biosciences Inc (NASDAQ: APTO ) ...

  • GlobeNewswire

    The European Medicines Agency Accepts the Regulatory Submission for Lumoxiti in Relapsed or Refractory Hairy Cell Leukemia

    Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for Lumoxiti® (moxetumomab pasudotox-tdfk), a first-in-class medicine indicated for adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog. “If approved by the EMA, Lumoxiti will be the first treatment available in Europe for relapsed or refractory hairy cell leukemia patients in more than twenty years, potentially changing the standard of care for these patients,” commented Pierre Dodion, MD, Executive Vice President and Chief Medical Officer of Innate Pharma.

  • GlobeNewswire

    The European Medicines Agency accepts the regulatory submission for Lumoxiti in relapsed or refractory hairy cell leukemia

    Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for Lumoxiti® (moxetumomab pasudotox-tdfk), a first-in-class medicine indicated for adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

  • GlobeNewswire

    Innate Pharma Provides Update on Lacutamab TELLOMAK Trial

    Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced an update regarding its TELLOMAK Phase II trial evaluating the efficacy and safety of lacutamab (IPH4102, a potentially first-in-class anti-KIR3DL2 antibody). Lacutamab will not be administered to new patients in the TELLOMAK trial until additional feedback is received from the respective regulatory agencies overseeing our clinical trial.

  • GlobeNewswire

    Innate Pharma highlights FDA-approved Lumoxiti® at ASH 2019

    Final analysis expands on efficacy results from pivotal Phase III trial of Lumoxiti in hairy cell leukemia; durable, complete responses maintained in long-term.

  • GlobeNewswire

    INNATE PHARMA RELEASES ITS FINANCIAL CALENDAR FOR 2020

    Innate Pharma SA (the “Company” - Euronext Paris: FR0010331421 – IPH; Nasdaq: IPHA) today released its 2020 financial calendar: March 10, 2020:         Publication of 2019.

  • Introducing Innate Pharma (EPA:IPH), The Stock That Slid 62% In The Last Three Years
    Simply Wall St.

    Introducing Innate Pharma (EPA:IPH), The Stock That Slid 62% In The Last Three Years

    If you love investing in stocks you're bound to buy some losers. But the long term shareholders of Innate Pharma S.A...